SPRYD7 and colorectal carcinoma: In this sense, future research exploring the feasibility of using pharmacological inhibitors and knockdown of SPRYD7 to assess the impact of SPRYD7 inhibition on cellular phenotypes, as well as to investigate the potential synergistic effect of targeting SPRYD7 in combination with standard CRC therapies, are warranted in order to explore the potential of SPRYD7 as a therapeutic target for CRC and for CRC metastasis treatment.